[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Lachmann, 2010 - Google Patents

Treatments for lysosomal storage disorders

Lachmann, 2010

View PDF
Document ID
9687304750576497981
Author
Lachmann R
Publication year
Publication venue
Biochemical Society Transactions

External Links

Snippet

There are over 70 human diseases that are caused by defects in various aspects of lysosomal function. Until 20 years ago, the only specific therapy available for lysosomal storage disorders was allogeneic haemopoietic stem cell transplantation. Over the last two …
Continue reading at citeseerx.ist.psu.edu (PDF) (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application

Similar Documents

Publication Publication Date Title
Biffi Hematopoietic stem cell gene therapy for storage disease: current and new indications
D’Avanzo et al. Mucopolysaccharidosis type II: one hundred years of research, diagnosis, and treatment
Parenti et al. Lysosomal storage diseases: from pathophysiology to therapy
Coutinho et al. Less is more: substrate reduction therapy for lysosomal storage disorders
Tolar et al. Combination of enzyme replacement and hematopoietic stem cell transplantation as therapy for Hurler syndrome
Brooks et al. Stop-codon read-through for patients affected by a lysosomal storage disorder
Li Enzyme replacement therapy: a review and its role in treating lysosomal storage diseases
Ries Enzyme replacement therapy and beyond—in memoriam Roscoe O. Brady, MD (1923–2016)
Benetó et al. Sanfilippo syndrome: molecular basis, disease models and therapeutic approaches
Parenti et al. Pharmacological chaperone therapy: preclinical development, clinical translation, and prospects for the treatment of lysosomal storage disorders
Beck Therapy for lysosomal storage disorders
Paciotti et al. Lysosomal ceramide metabolism disorders: implications in Parkinson’s disease
Valstar et al. Sanfilippo syndrome: a mini-review
Pastores et al. Clinical neurogenetics: neuropathic lysosomal storage disorders
Pastores et al. Current and emerging therapies for the lysosomal storage disorders
Pará et al. Neuropathophysiology of lysosomal storage diseases: synaptic dysfunction as a starting point for disease progression
Lachmann Treatments for lysosomal storage disorders
Datta et al. Enzyme therapy: a forerunner in catalyzing a healthy society?
van Gelder et al. Treatment options for lysosomal storage disorders: developing insights
Kirkegaard Emerging therapies and therapeutic concepts for lysosomal storage diseases
Huynh et al. Biochemical evidence for superior correction of neuronal storage by chemically modified enzyme in murine mucopolysaccharidosis VII
Keeling Nonsense suppression as an approach to treat lysosomal storage diseases
Ellison et al. Advances in therapies for neurological lysosomal storage disorders
Segatori Impairment of homeostasis in lysosomal storage disorders
Vitner et al. Emerging therapeutic targets for Gaucher disease